Table 2.

Synthesis of the molecular tests’ diagnostic performance.

Panel	Thyroseq v3	Thyroseq v2	Afirma GSC	Afirma GEC
No of studies	4	9	4	25
SENS [95% CI]	0.99 [0.90–1.00]	0.86 [0.81–0.90]	0.95 [0.86–0.90]	0.97 [0.93–0.98]
SPEC [95% CI]	0.64 [0.32–0.87]	0.75 [0.63–0.90]	0.51 [0.33–0.69]	0.19 [0.15–0.24]
PLR [95% CI]	2.8 [1.2–6.3]	3,5 [2.2–5.6]	1,9 [1.3–2.8]	1.2 [1.1–1.3]
NLR [95% CI]	0.02 [0.00–2.69]	0.18 [0.12–0.27]	0.11 [0.04–0.27]	0.18 [0.10–0.33]
PPV [95% CI]	0.78 [0.68–0.88]	0.51 [0.41–0.60]	0.60 [0.52–0.68]	0.39 [0.37–0.40]
NPV [95% CI]	0.96 [0.83–0.88]	0.95 [0.85–1.00]	0.91 [0.80–0.68]	0.91 [0.88–0.93]
DOR [95% CI]	157 [1–18723]	19 [9–42]	18 [6–53]	7 [3–13]
AUC [95% CI]	0.95 [0.93–0.97]	0.88 [0.85–0.90]	0.90 [0.87–0.92]	0.60 [0.56–0.65]
BCR	0.53	0.74	0.73	0.42

AUC, area under the curve; CI, confidence interval; DOR, diagnostic odds ratio; GEC, gene expression classifier; GSC, gene sequencing classifier; NLR, negative likelimehood ratio; No, number; PLR, positive likelihood ratio; SENS, sensitivity; SPEC, specificity.